Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Objective: Results of randomized clinical trials (RCT) demonstrate that novel oral
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …

Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …

Objective Our objective was to assess the cost effectiveness of apixaban versus edoxaban
in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …